Status: Recruiting
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
Participants needed: 65
Trial details
Phase: Phase 3Age: 8-18Biological sex: AllType: InterventionalSponsor: Alfasigma S.p.A.Updated: Jun 12, 2026Locations: 14
Eligibility criteria
Subject and/or parent/legal guardian must be able and willing to comply with the... [+8]
Subject with a body weight <15 kg. [+7]